UK markets closed

Celyad Oncology SA (0QFK.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.3680-0.0010 (-0.27%)
At close: 04:50PM BST
Currency in EUR

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.30
52-week change 3-67.61%
S&P500 52-week change 322.36%
52-week high 31.2250
52-week low 30.0000
50-day moving average 30.5072
200-day moving average 30.6023

Share statistics

Avg vol (3-month) 31.1k
Avg vol (10-day) 31.54k
Shares outstanding 511.94M
Implied shares outstanding 6N/A
Float 811.86M
% held by insiders 17.63%
% held by institutions 135.50%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-8,110.35%

Management effectiveness

Return on assets (ttm)-33.03%
Return on equity (ttm)-159.08%

Income statement

Revenue (ttm)102k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -9M
Net income avi to common (ttm)-8.45M
Diluted EPS (ttm)-1.4420
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)7M
Total cash per share (mrq)0.17
Total debt (mrq)1.06M
Total debt/equity (mrq)16.78%
Current ratio (mrq)3.79
Book value per share (mrq)0.15

Cash flow statement

Operating cash flow (ttm)-15.2M
Levered free cash flow (ttm)-14.45M